UBS Group’s Mead Johnson Nutrition Company MJN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-1,947,990
Closed -$174M 8336
2017
Q1
$174M Buy
1,947,990
+1,796,229
+1,184% +$148M 0.09% 236
2016
Q4
$10.7M Buy
151,761
+27,293
+22% +$2.03M 0.01% 1440
2016
Q3
$9.84M Sell
124,468
-26,618
-18% -$2.27M 0.01% 1429
2016
Q2
$13.7M Sell
151,086
-13,174
-8% -$1.12M 0.01% 1174
2016
Q1
$14M Sell
164,260
-6,695
-4% -$498K 0.01% 1105
2015
Q4
$13.5M Buy
170,955
+23,932
+16% +$1.89M 0.01% 1200
2015
Q3
$10.3M Buy
147,023
+51,368
+54% +$4.23M 0.01% 1336
2015
Q2
$8.63M Sell
95,655
-115,719
-55% -$11.2M 0.01% 1583
2015
Q1
$21.2M Sell
211,374
-24,280
-10% -$2.45M 0.01% 917
2014
Q4
$23.7M Buy
+235,654
New +$23.5M 0.02% 893

Other funds holding MJN

UBS Group's MJN Position: Q2 2017 in Review

UBS Group sold out of Mead Johnson Nutrition Company (MJN) in Q2 2017, closing a stake of 1,947,990 shares — an estimated $174M sold.

UBS Group first reported a position in MJN in Q4 2014 and held it in 10 quarters. The position peaked at $174M in Q1 2017. 7 funds tracked by Wall St. Rank hold MJN as of Q2 2017.

  • UBS Group reported no remaining Mead Johnson Nutrition Company position as of Q2 2017 after selling out during the quarter.
  • UBS Group sold 1,947,990 Mead Johnson Nutrition Company shares in Q2 2017, an estimated $174M.
  • UBS Group first reported a position in Mead Johnson Nutrition Company in Q4 2014 and held it in 10 quarters.
  • UBS Group's Mead Johnson Nutrition Company position peaked at $174M in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Mead Johnson Nutrition Company as of Q2 2017.

Based on UBS Group's 13F filing for Q2 2017, filed 14 Aug 2017.